



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Blocklisting Six Monthly Return

London: Monday, 31 December 2012: Chi-Med announces the following blocklisting six monthly return:

1. Name of applicant:	Hutchison China MediTech Limited
2. Name of scheme:	Hutchison China MediTech Limited Share Option Scheme
3. Period of return:	From 29 June 2012 to 28 December 2012
4. Balance under scheme from previous return:	1,786,254 ordinary shares of US\$1 each
5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:	Nil
6. Number of securities issued/allotted under scheme during period:	61,975 ordinary shares of US\$1 each
7. Balance under scheme not yet issued/allotted at end of the period:	1,724,279 ordinary shares of US\$1 each
8. Number and class of securities originally listed and the date of admission:	2,560,606 ordinary shares of US\$1 each admitted on 26 June 2007
9. Total number of securities in issue at the end of the period:	52,048,448 ordinary shares of US\$1 each
Name of contact:	Christian Hogg
Address of contact:	21/F., Hutchison House, 10 Harcourt Road, Hong Kong
Telephone number of contact:	+852 2121 8200

Ends

Enquiries

Chi-Med Telephone: +852 2121 8200
Christian Hogg, CEO

Panmure Gordon (UK) Limited Telephone: +44 20 7886 2500
Richard Gray
Andrew Potts
Grishma Patel

Citigate Dewe Rogerson Telephone: +44 20 7638 9571
Anthony Carlisle Mobile: +44 7973 611 888
David Dible Mobile: +44 7967 566 919

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.